Re-challenge Pembrolizumab Study as a Second or Further Line in Patients With Advanced NSCLC

PHASE2CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

July 15, 2018

Primary Completion Date

December 30, 2022

Study Completion Date

March 9, 2023

Conditions
Lung Cancer
Interventions
DRUG

Pembrolizumab

200 mg, Q3W

DRUG

Pembrolizumab

200 mg, Q3W

Trial Locations (19)

15006

Complejo Hospitalario de la Coruña, A Coruña

17007

Hospital Dr. Josep Trueta, Girona

23007

Complejo Hospitalario de Jaén, Jaén

24071

Complejo Asistencial Universitario de León, León

28040

Fundación Jiménez Díaz, Madrid

28041

H. 12 de Octubre, Madrid

31008

Clínica Universidad de Navarra, Pamplona

46014

Hospital General Universitario de Valencia, Valencia

46026

Hospital La Fe, Valencia

48013

Hospital de Basurto, Bilbao

50009

Hospital Miguel Servet, Zaragoza

03203

Hospital General Universitario de Elche, Elche

08916

H. Germans Trias i Pujol, Badalona

08208

Hospital Parc Taulí, Sabadell

08227

Consorci Sanitari de Terrassa, Terrassa

08025

Hospital de Santa Creu i Sant Pau, Barcelona

08035

H.U.Vall D´Hebrón, Barcelona

Unknown

Puerta de Hierro, Madrid

07198

H. Son Llàtzer, Palma de Mallorca

All Listed Sponsors
lead

Spanish Lung Cancer Group

OTHER

NCT03526887 - Re-challenge Pembrolizumab Study as a Second or Further Line in Patients With Advanced NSCLC | Biotech Hunter | Biotech Hunter